Chief Medical Officer, Dr. Aron Tendler, and Chief Executive Officer, Dr. Christopher von Jako are interviewed by Medtech Insight, describing how despite the shift to teletherapy during the COVID-19 pandemic, the need for TMS treatment will be greater than ever in the near future.
Comentarios